An in vivo avian model of human melanoma to perform rapid and robust preclinical studies

An in vivo avian model of human melanoma to perform rapid and robust preclinical studies

Abstract Metastatic melanoma patients carrying a BRAFV600 mutation can be treated with a combination of BRAF and MEK inhibitors (BRAFi/MEKi), but innate and acquired resistance invariably occurs. Predicting patient response to targeted therapies is crucial to guide clinical decision. We describe her...

Full description

Bibliographic Details
Main Authors: Loraine Jarrosson, Stéphane Dalle, Clélia Costechareyre, Yaqi Tang, Maxime Grimont, Maud Plaschka, Marjorie Lacourrège, Romain Teinturier, Myrtille Le Bouar, Delphine Maucort‐Boulch, Anaïs Eberhardt, Valérie Castellani, Julie Caramel, Céline Delloye‐Bourgeois
Format: Article
Language:English
Published: Springer Nature 2023-03-01
Series:EMBO Molecular Medicine
Subjects:
avian model
melanoma
patient‐Derived Xenografts
preclinical oncology
targeted therapies
Online Access:https://doi.org/10.15252/emmm.202216629

Internet

https://doi.org/10.15252/emmm.202216629

Similar Items